Cancer biology explores the complex ways cells grow out of control, investigating the genetic mutations and environmental factors that drive tumor formation. This field seeks to understand how healthy cells transform into malignant ones and how these rogue cells spread throughout the body. By decoding these fundamental mechanisms, researchers aim to develop more effective treatments that target the disease at its source while sparing healthy tissue.

At Gist.Science, we process every new preprint published in this category directly from bioRxiv to ensure you stay ahead of the curve. Our team provides both accessible plain-language overviews and detailed technical summaries for each study, bridging the gap between raw research data and practical understanding. Whether you are a specialist or a curious reader, our goal is to make these critical findings clear and actionable.

Below are the latest papers in cancer biology, offering fresh insights into the ongoing fight against this disease.

WITHDRAWN: A Druggable Tumor Suppressor and Leukemic Stem Cell Marker

This study identifies the absence of the tumor suppressor AT2R as a key marker for chemotherapy-resistant leukemic stem cells in acute myeloid leukemia, demonstrating that epigenetic silencing of AT2R drives disease progression through fatty acid metabolism and that its pharmacological activation with the agonist buloxibutid (C21) effectively inhibits leukemogenesis and enhances chemotherapy efficacy.

Pan, Y., Wang, C., Meng, X., Zhou, W., Hammer, R., Zheng, H., Hildebrandt, G., Kang, X.2026-03-11📄 cancer biology

A MET-Targeted Variable New Antigen Receptor Theranostic for Non-Small Cell Lung Cancer

This study reports the development and preclinical validation of a shark-derived VNAR-based theranostic agent, vMET1-Fc, which enables high-contrast PET imaging and effective targeted radiotherapy for MET-altered non-small cell lung cancer with a favorable safety profile.

LeBeau, A., Minne, R., West, J., Luo, N., Nickel, K., Gunaratne, G., Ott, K., Gallant, J., Barrett, K., Mork, C., Wopat, M., Zitzer, N., Javeri, S., Lopez, L., Toscano, W., Kwon, O., Teague, J., Bunke (…)2026-03-11📄 cancer biology

Targeting NF-κB epigenetic activation and DNA repair deficiency in G34-mutant pediatric diffuse hemispheric glioma with nanoparticles combining PARP inhibition and immune stimulation mediated by CpG dinucleotides

This study demonstrates that G34-mutant pediatric diffuse hemispheric gliomas can be targeted by HDL nanoparticles co-delivering CpG dinucleotides to stimulate NF-κB-mediated immune responses and olaparib to exploit DNA repair deficiencies, thereby offering a promising therapeutic strategy for these aggressive tumors.

Haase, S., Banerjee, K., Mujeeb, A. A., Halseth, T., Liu, L., Yu, M., Sriramulu, S., Sheth, M., Raghuram, S., Lowenstein, P. R., Schwendeman, A., Castro, M. G.2026-03-11📄 cancer biology

DRP1-mediated mitochondrial fission integrates growth hormone signaling with metabolic and stress adaptation in triple-negative breast cancer

This study demonstrates that growth hormone drives triple-negative breast cancer progression by activating DRP1-mediated mitochondrial fission, which is essential for linking metabolic reprogramming toward glycolysis with cell proliferation and the modulation of the inflammatory tumor microenvironment.

Gomes, J. M. M., Pereira, M. T., Silva, L. M., Goncalves, L. E. D., Amaral, M. A., Paredes, L. C., Fenero, C. M., Padovani, B. N., Cruz, M. C., Camara, N. O. S.2026-03-10📄 cancer biology

Multi-omics and functional analysis of a bioengineered vascularized pancreatic cancer model reveal an immunosuppressive and therapy-resistant niche

This study utilizes an integrated multi-omics approach on bioengineered, vascularized pancreatic cancer spheroids to characterize a therapy-resistant, immunosuppressive tumor niche that recapitulates patient heterogeneity and provides a powerful translational platform for developing new PDAC treatments.

Giustarini, G., Kok Siong, A., Kumar, P., Teng, G., Kuok, B. Z. X., Tan, C. X., Bhalla, R., Kalaitsidou, E., Tay, A., Howland, S. W., Cappello, P., Wu, W., Chen, J., Albani, S., Adriani, G.2026-03-09📄 cancer biology

Driving proteomic imbalance in malignancy provokes proteomic catastrophe and confers tumor suppression

This study demonstrates that depleting the oncogenic factor HSF1 in malignant cells triggers a catastrophic proteomic imbalance and amyloidogenesis that can be exploited for tumor suppression, whereas HSF1 is dispensable for non-transformed cells, highlighting a novel therapeutic strategy to combat malignancy by provoking proteomic catastrophe.

Ram, B. M., Shriwas, O., Xu, M., Chuang, K.-H., Dai, C.2026-03-06📄 cancer biology